

16 September 2025

**Chrysalis Investments Limited ("Chrysalis" or the "Company")**

**Transaction in own shares**

The Company announces that, in accordance with the terms of its share buyback programme (the "Programme") announced on 26 September 2024, it has repurchased the following number of its ordinary shares through Panmure Liberum.

Date of Purchase	15 September 2025
Number of ordinary shares purchased	250,000
Weighted average price paid (£)	1.238775

All Ordinary Shares purchased will be held in treasury. Following the above purchase, the Company holds 82,900,876 Ordinary Shares in treasury.

The total number of Ordinary Shares in issue excluding shares held as treasury shares is 512,249,538.

The above figure of 512,249,538 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

-ENDS-

**For further information, please contact**

**Media**

**Montfort Communications:**

Charlotte McMullen / Imogen Saunders

**+44 (0) 7921 881 800**

chrysalis@montfort.london

**Investment Adviser**

**Chrysalis Investment Partners LLP:**

James Simpson

**+44 (0) 20 7871 5343**

**G10 Capital Limited (AIFM):**

Maria Baldwin

**+44 (0) 20 7397 5450**

**Barclays Bank PLC:**

Dion Di Mceli / Stuart Muress / James Atkinson

**+44 (0) 20 7623 2323**

**Panmure Liberum:**

Chris Clarke / Darren Vickers

**+44 (0) 20 3100 2222**

**Deutsche Numis:**

Nathan Brown / Matt Goss

**+44 (0) 20 7260 1000**

**IQEQ Fund Services (Guernsey) Limited:**

Aimee Gontier / Elaine Smeja

**+44 (0) 1481 231852**

LEI: 213800F9SQ753JQH5W24

A copy of this announcement will be available on the Company's website at <https://www.chrysalisinvestments.co.uk>

The information contained in this announcement regarding the Company's investments has been provided by the relevant underlying portfolio company and has not been independently verified by the Company. The information contained herein is unaudited.

This announcement is for information purposes only and is not an offer to invest. All investments are subject to risk. Past performance is no guarantee of future returns. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. The value of investments may fluctuate. Results achieved in the

professional advice before making any investment decision. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. Neither the content of the Company's website, nor the content on any website accessible from hyperlinks on its website for any other website, is incorporated into, or forms part of, this announcement nor, unless previously published by means of a recognised information service, should any such content be relied upon in reaching a decision as to whether or not to acquire, continue to hold, or dispose of, securities in the Company.

The Company is an alternative investment fund ("AIF") for the purposes of the AIFMDirective and as such is required to have an investment manager who is duly authorised to undertake the role of an alternative investment fund manager ("AIFM"). The AIFM appointed is G10 Capital Limited (part of the IQEQ Group). Chrysalis Investment Partners LLP (FRN: 1009684) is an Appointed Representative of G10 Capital (FRN: 648953) Limited, which is authorised and regulated by the Financial Conduct Authority.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSEELFFEKLEBBE